IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 62nd Annual ASH Meeting

Rhea-AI Summary

IGM Biosciences, a clinical-stage biotechnology firm, will host a conference call and live audio webcast on December 5, 2020, at 2:00 p.m. ET. This event follows the first clinical data presentation of IGM-2323 from their Phase 1 trial at the 62nd American Society of Hematology Annual Meeting. Interested parties can access the call by dialing (866) 649-1996 or (409) 217-8769, using conference ID 1141638. The call will also be available via a live webcast on their website, with a replay accessible for 90 days afterward.

MOUNTAIN VIEW, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday, December 5, 2020, at 2:00 p.m. ET. The event will take place following a poster presentation featuring the first clinical data from the Company’s Phase 1 trial evaluating IGM-2323 at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

The conference call may be accessed by dialing (866) 649-1996 (domestic) or (409) 217-8769 (international) and referring to conference ID 1141638. A live webcast of the presentation will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

FAQ

What is the date and time of IGM Biosciences' conference call?

The conference call is scheduled for December 5, 2020, at 2:00 p.m. ET.

How can I access the IGM Biosciences conference call?

You can access the call by dialing (866) 649-1996 for domestic calls or (409) 217-8769 for international calls, using conference ID 1141638.

Where can I find the live audio webcast of IGM Biosciences' presentation?

The live audio webcast can be found on the 'Events and Presentations' page in the 'Investors' section of IGM Biosciences' website.

What is the focus of IGM Biosciences as stated in the press release?

IGM Biosciences focuses on creating and developing engineered IgM antibodies.

What clinical data will be presented during the IGM Biosciences event?

The event will present the first clinical data from the Phase 1 trial evaluating IGM-2323.

How long will the replay of the IGM Biosciences webcast be available?

The replay of the webcast will be available for 90 days following the presentation.